Best in Biotech 14 Nov 2024 8 biotech companies advancing new treatments for breast cancer in 2024 Delve into the diverse landscape of breast cancer treatment with nine biotech companies currently developing new treatments. November 14, 2024 - 12 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 4 Nov 2024 Top biotech deals of October 2024 Discover the major biotech partnerships, collaborations and mergers and acquisitions that made headlines in October 2024. November 4, 2024 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Podcast 11 Oct 2024Bispecific ADCs: the next generation of cancer treatments To talk about bispecific ADCs, and biotechs in Czechia, our conversation this week is with Radek Špíšek, CEO of SOTIO. October 11, 2024 Share WhatsApp Twitter Linkedin Email Listen Now Apple Music Spotify More
Sponsored by KBI Biopharma 17 Sep 2024 ADCs that deliver: The secret lies in rigorous characterization Explore the challenges of ADC characterization, key techniques, and the benefits of partnering with a CDMO for effective development. September 17, 2024 - 7 minutesmins - By Ute Boronowsky Share WhatsApp Twitter Linkedin Email
News and Trends 4 Sep 2024 2024: a year of breakthroughs for endometrial cancer? New treatments have been approved by regulators for endometrial cancer, which are regarded as major therapeutic breakthroughs. September 4, 2024 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Podcast 21 Jun 2024How ADCs can deliver death cap mushroom toxins to treat cancer Listen to our conversation with Heidelberg Pharma about its lead amanitin-based ADC product candidate, HDP-101. June 21, 2024 Share WhatsApp Twitter Linkedin Email Listen Now Apple Music Spotify More
Best in Biotech 8 Feb 2024 Fourteen biotech companies spearheading the antibody drug conjugate industry The antibody-drug conjugate market has gained significant traction recently. Discover some of the top ADC companies in the industry. February 8, 2024 - 18 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 20 Nov 2023 M&As: what’s up with the ADC buying spree? Antibody drug conjugates (ADCs) have been much sought-after through investments of late, with big pharma eyeing these drugs developed by various biotechs, to eventually nab them. With yet another ADC being bought by Bristol Myers Squibb, and AbbVie’s proposed $10 billion deal to seize ImmunoGen’s oncology pipeline, are these drugs the golden ticket to targeted […] November 20, 2023 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 13 Oct 2023 How close are we to a cure for metastatic breast cancer? Currently considered an incurable disease, there is a lot of work being done around developing better treatment options for metastatic breast cancer, and, ultimately, a cure. Numerous promising candidates are in clinical trials, all with the hope of progressing toward U.S. Food and Drug Administration (FDA) approval. According to the World Health Organization (WHO), 2.3 […] October 13, 2023 - 8 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 27 Jul 2023 Epsilogen completes first clinical trial of IgE antibody to treat cancer Epsilogen, a producer of immunoglobulin E (IgE) antibodies to treat cancer, has published the final phase I data from the first ever clinical trial of an IgE antibody therapeutic. The results were published in Nature Communications. MOv18 IgE is Epsilogen’s lead IgE antibody drug candidate and binds to anti-folate receptor (FRα), a well validated target […] July 27, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 26 Jul 2023 Antibody drug conjugates: BiVictriX drives a new era in cancer medicine The first-ever antibody-drug conjugate (ADC) to be approved, gemtuzumab ozogamicin, raised hope for a new class of drugs to treat cancer. But the drug was then withdrawn following a black box warning after patients experienced adverse side effects, and there had been fatalities. But this didn’t discourage biopharmas looking to create safer alternatives from expediting […] July 26, 2023 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Podcast 7 Jul 2023Beyond Biotech podcast 53: Antibody-drug conjugates On the podcast this week, we have a conversation about antibody-drug conjugates with Pejvack Motlagh, who was recently announced as the chief medical officer at Mablink Bioscience. Mablink Bioscience Mablink Bioscience is a biotechnology company developing the next generation of an emerging class of cancer drugs, antibody-drug conjugates (ADCs). Mablink’s patented hydrophilic drug-linker technology, PSARLink, […] July 7, 2023 Share WhatsApp Twitter Linkedin Email